It appears Chazzledazzle's reply to my post has be

It appears Chazzledazzle's reply to my post has been deleted for some reason but here is my reply to his reply -

When have we ever seen LL have a negative result on other cytokines?

You wrote -

" But a higher dose at 700mg may have had an additional negative affect on other cytokines."

Wouldn't a negative affect on other cytokines result in Adverse Events? When has that ever shown up in use of Leronlimab? AEs are reported events to the FDA, remember. What is LL record in this regard?

Leronlimab is an immune system moderator. It coaxes the immune system systemically to homeostasis. It does this regardless of what indication it may be used to treat.

THERE IS NO SPECIFIC TARGETING OF ANY MORBIDITY. That is left up to THE IMMUNE SYSTEM ITSELF!

I'm not using CAPS to shout but to emphasis this truth about how LL works - every time! - unless there are genetic variations affecting CCR5 receptors in some individuals.

WE may use LL to target different morbidities but LL doesn't "care". It does what it does - bind to CCR5 - and a person's body and immune system has to take it from there. Then we can test for efficacy against specific morbidities.